Altimmune (ALT) Free Cash Flow (2010 - 2026)
Altimmune (ALT) reported Free Cash Flow of -$21.0 million for Q1 2026, down 24.48% year-over-year from -$27.8 million in Q1 2025, and down 7.78% quarter-over-quarter from -$19.4 million in Q4 2025.
Altimmune (ALT) Free Cash Flow (2010 - 2026) Analysis & Trends
Altimmune (ALT) has 17 years of Free Cash Flow data on file, last reported at -$21.0 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$21.0 million, down 24.48% year-over-year; the trailing twelve-month figure through Mar 2026 was -$71.7 million (up 10.8% YoY), and the FY2025 annual result was -$67.5 million, up 15.41% from the prior year.
- Free Cash Flow retreated to -$21.0 million in Q1 2026 per ALT's latest filing, from -$19.4 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$11.9 million in Q3 2025 and troughed at -$27.1 million in Q3 2024.
- A 5-year average of -$18.1 million and a median of -$18.1 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow sank 43.76% in 2023, then soared 56.13% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$17.3 million in 2022, then increased by 4.68% to -$16.5 million in 2023, then retreated by 10.48% to -$18.3 million in 2024, then retreated by 6.48% to -$19.4 million in 2025, then dropped by 7.78% to -$21.0 million in 2026.
- Business Quant data shows ALT's Free Cash Flow at -$21.0 million in Q1 2026, -$19.4 million in Q4 2025, and -$11.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | -20.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.96 Mn |
| Mar 31, 2026 | -20.96 Mn |
| Dec 31, 2025 | -19.45 Mn |
| Dec 31, 2025 | -19.45 Mn |
| Sep 30, 2025 | -11.90 Mn |
| Sep 30, 2025 | -11.90 Mn |
| Jun 30, 2025 | -19.35 Mn |
| Jun 30, 2025 | -19.35 Mn |
| Mar 31, 2025 | -16.84 Mn |
| Mar 31, 2025 | -16.84 Mn |
| Dec 31, 2024 | -18.27 Mn |
| Dec 31, 2024 | -18.27 Mn |
| Sep 30, 2024 | -27.12 Mn |
| Sep 30, 2024 | -27.12 Mn |
| Jun 30, 2024 | -18.11 Mn |
| Jun 30, 2024 | -18.11 Mn |
| Mar 31, 2024 | -16.36 Mn |
| Mar 31, 2024 | -16.36 Mn |
| Dec 31, 2023 | -16.53 Mn |
| Dec 31, 2023 | -16.53 Mn |